article thumbnail

Cholesterol may not be the only lipid involved in trans fat-driven cardiovascular disease

Medical Xpress - Cardiology

Excess cholesterol is known to form artery-clogging plaques that can lead to stroke, arterial disease, heart attack, and more, making it the focus of many heart health campaigns. But what if there's more to the picture than just cholesterol?

article thumbnail

Should You Take A Statin To Lower Your Cholesterol?

Dr. Paddy Barrett

Only when you have a clear idea of those three factors can you decide whether or not to take a medication to lower your LDL cholesterol. I use statins in the question posed above because that is what most people think and, in fact, what they will start with when looking to lower their LDL cholesterol with a medication. Not zero risk.

article thumbnail

Unexplained changes in cholesterol may help identify older adults at risk for dementia

American Heart News - Heart News

indicates that cholesterol levels that fluctuate significantly from year to year without a change in medication may someday help to identify those with a higher risk of developing. Research Highlights: A study of older adults in Australia and the U.S.

article thumbnail

Association of cumulative non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio with the risk of cardiometabolic disease

Frontiers in Cardiovascular Medicine

BackgroundOne measurement of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) is considered to be associated with insulin resistance and cardiovascular disease (CVD) risk.

article thumbnail

Cholesterol crystals in the pathogenesis of atherosclerosis

Nature Reviews - Cardiology

Nature Reviews Cardiology, Published online: 18 November 2024; doi:10.1038/s41569-024-01100-3 Cholesterol crystals (CCs) have a pathogenic role in various cardiovascular diseases, particularly atherosclerosis.

article thumbnail

Novel PCSK9 Inhibitor Cut LDL Cholesterol Levels by More Than Half

DAIC

milla1cf Sun, 04/07/2024 - 18:09 April 7, 2024 — Among patients at high or very high risk for a heart attack or stroke, the addition of the investigational drug lerodalcibep to standard cholesterol-lowering medication for one year reduced LDL, or “bad” cholesterol, levels by more than half on average, compared with a placebo.

article thumbnail

Third-Generation PCSK9 Inhibitor Cuts Cholesterol With Single, Small, Monthly Shot

Med Page Today

(MedPage Today) -- ATLANTA -- A novel PCSK9 inhibitor safely reduced LDL cholesterol levels with just a single, quick, once-monthly dose, the phase III LIBerate-HR trial showed. Lerodalcibep reduced LDL cholesterol by 56% more than placebo from.